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eter Libby, MD,*‡ Paul M Ridker, MD, MPH*†‡
oston, Massachusetts
The concept that inflammation governs atherosclerosis and its complications has provided a
new unifying hypothesis of the links between risk factors and the cellular and molecular
alterations that underlie this disease. This new mechanistic insight has already begun to
translate into changes in clinical practice. The preponderance of available data supports the
predictive power of biomarkers of inflammation such as high-sensitivity C-reactive protein
(hsCRP) in broad categories of individuals, both those who are apparently well and those with
already-manifest atherosclerotic cardiovascular disease. The demonstrated clinical utility of
hsCRP and potentially of other inflammatory biomarkers has engendered intense interest in
evaluating their cost-effectiveness as predictive tools beyond conventional risk markers and as
goals for therapy. The rapid translation of inflammation biology in cardiovascular disease
from the laboratory to the clinic serves as a gratifying example of bench-to-bedside research.
Ultimately, the insight that inflammation plays a fundamental role in atherosclerosis may lead
to novel therapies that target aspects of the inflammatory process smoldering within the
atheroma. (J Am Coll Cardiol 2006;48:A33–46) © 2006 by the American College of
ublished by Elsevier Inc. doi:10.1016/j.jacc.2006.08.011Cardiology Foundation
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cur view of atherosclerosis has evolved strikingly over the
ast several decades. For over 50 years, the medical commu-
ity regarded atherosclerosis as a cholesterol storage disease
haracterized by passive deposition of lipid in the arterial
all. According to this concept, continuing accumulation of
atty debris encrusted the artery, causing progressive stenosis
hat ultimately provoked occlusive thrombosis. Accumulat-
ng data and evolution in our thinking cast doubt on this
imple concept of atherothrombosis over the last quarter
entury. Today, we increasingly understand atherogenesis as
n active process that involves altered cellular behavior in
esponse to defined molecular signals. We no longer regard
he blood vessel as an inert tube, but rather as a living
tructure composed of cells such as endothelium and
mooth muscle (Fig. 1). We possess increasingly detailed
nowledge of the interactions between blood components,
ncluding cells, proteins, and small molecules, and the
ntrinsic cells that populate the normal artery wall as
ontributors to the pathogenesis of this disease.
Current thinking accords a primordial role to inflamma-
ion as a common unifying mechanism that links risk factors
o lesion formation and their tendency to provoke throm-
otic complications. We provide here an overview of the
asic and population science that underlies this newfound
nderstanding of this ubiquitous disease. Advances in our
nderstanding of the pathogenesis of atherothrombosis have
mplications beyond theory and now cross the threshold to
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ccepted June 13, 2006.linical practice. This article explores further the translation
f basic and population science to clinical practice.
For convenience, we often consider atherogenesis in distinct
hronologic phases (Figs. 1 to 4). In contemporary society,
he first phase, initiation, occurs all too frequently in
hildhood or adolescence (Figs. 1 and 2). The nascent lesion
hen enters a phase of progression, generally considered to
ccur during young adulthood through middle life (Fig. 3).
ltimately, atherosclerotic disease becomes manifest with
ither chronic, stable symptoms or thrombotic complica-
ions such as acute myocardial infarction or ischemic stroke
Fig. 4). Traditionally, the latter phase of atherothrombosis,
omplication, occurs in the middle-age or elderly individual.
learly, this timeline of atherogenesis greatly oversimplifies
complex process. Indeed, individuals with atherosclerosis
ave lesions with anatomopathological characteristics of
ore than one stage that coexist, often close proximity. For
xample, aortae of individuals with atherosclerotic disease
an often harbor within centimeters a fatty streak, a fibrous
laque, a calcified lesion, and an ulcerated plaque with
hrombosis in situ. Nonetheless, for pedagogical purposes,
eparating the discussion of atherosclerosis into the phases
f lesion initiation, progression, and complication proves
onvenient.
NFLAMMATION AND THE
NITIATION OF ATHEROSCLEROSIS
ecent research has forged major advances in defining the
olecular mediators of classical and emerging risk factors
or atherosclerosis. Our knowledge of the links between risk
actors and pathobiology remains incomplete. Current con-
epts will doubtless undergo expansion and revision. Yet,
ata obtained to date point strongly to inflammation as a
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Inflammation and Atherothrombosis November 7, 2006:A33–46nal common pathway for transducing the effects of risk
actors into changes in the biology of the arterial wall (1–3).
For example, laboratory and population studies con-
ucted over the last century consistently have identified
holesterol as a potent risk factor for atherosclerosis and its
omplications. Considerable evidence has established the
resence of oxidized components of low-density lipoprotein
LDL) in atherosclerotic lesions. Oxidized phospholipids,
ome with chemically defined structures, can act as proin-
ammatory stimuli that alter the behavior of intrinsic
ascular wall cells and leukocytes alike (4,5). Certain oxi-
ized phospholipids can elicit the expression on the surface
Abbreviations and Acronyms
EC  endothelial cell
ECM  extracellular matrix
HDL  high-density lipoprotein
hsCRP  high-sensitivity C-reactive protein
IL  interleukin
LDL-C  low-density lipoprotein cholesterol
·NO  nitric oxide
SMC  smooth muscle cell
igure 1. The transition from the normal artery wall to the nascent ath
onolayer of endothelial cells overlies the intimal layer and abuts a basem
mooth muscle cells and a layer of extracellular matrix. The internal elastic
ormally filled with quiescent smooth muscle cells embedded in an elastin-
xidative or inflammatory stress, they induce the expression of adhesion molecule
he intimal layer. This diagram does not depict the adventitia, the outermost laf vascular endothelial cells (EC) of well-characterized
dhesion molecules that mediate leukocyte adherence to the
umenal surface of these cells (Fig. 1). Likewise, constitu-
nts of oxidized LDL can stimulate the expression of
hemoattractant molecules, including chemokines such as
onocyte chemoattractant protein-1, that beckon the at-
ached leukocyte to migrate through the endothelial mono-
ayer and enter the arterial intima. Angiotensin II can also
timulate the expression of vascular cell adhesion
olecule-1 on the endothelial surface (6). Other cytokines
egulated by components of oxidized LDL can activate the
eukocytes within the intimal layer, provoking their produc-
ion of further inflammatory mediators (i.e., proinflamma-
ory cytokines and small lipid molecules such as the leuko-
rienes and prostaglandins). Moreover, these activated
eukocytes can generate reactive oxygen species that aug-
ent oxidant stress, the constant companion of inflamma-
ion in atherosclerosis (6). Concordant population studies
upport a relationship between hypertension and atheroscle-
otic cardiovascular disease consistently and convincingly.
onsiderable evidence now links high blood pressure to in-
ammation in the artery wall. In particular, angiotensin II,
lerotic lesion. The normal muscular artery has a trilaminar structure. A
embrane. In human arteries, the intima normally contains a few resident
a constitutes the boundary between the intimal layer and the tunica media,
xtracellular matrix. When molecules associated with risk factors stimulateerosc
ent m
lamin
rich es for leukocytes and chemoattractants that draw the bound leukocytes into
yer of the blood vessel.
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November 7, 2006:A33–46 Inflammation and Atherothrombosisonsidered a major mediator of hypertension, can act as a
roinflammatory stimulus. For example, angiotensin II can
timulate the expression of the proinflammatory cytokine
nterleukin (IL)-6 and the chemokine monocyte chemoat-
ractant protein-1 from arterial smooth muscle cells (SMC)
7,8). Angiotensin II augments the activity of the adenine
inucleotide phosphate oxidases by vascular wall cells. Such
nzymes give rise to superoxide anion, a major contributor
o oxidative stress in atherosclerotic lesions (9).
Once resident in the artery wall, mononuclear phagocytes
ransition from a peripheral blood monocyte to a tissue
acrophage (Fig. 2). In the artery wall, macrophages
ccumulate lipid derived from modified lipoprotein particles
nternalized through various families of scavenger receptors.
owever, lipid accumulation in the artery wall depends on
balance between entry and egress. Population studies have
onsistently established an inverse relationship between
igh-density lipoprotein (HDL) levels and atherosclerotic
ardiovascular disease. One major antiatherosclerotic role of
DL likely results from its ability to accept cholesterol from
igure 2. Formation of the fibrofatty plaque. The transition from the fatty
SMCs) from the tunica media through the internal elastic lamina into the i
nd elastin and can divide in response to mitogenic stimuli. The mononuc
ipoprotein (LDL) through scavenger receptors to form foam cells. The act
roinflammatory mediators including cytokines, and small lipid molecules
hen SMCs encounter fibrogenic stimuli such as transforming growth f
ncluding fibrillar collagen, depicted by the triple helical structures in theipid-engorged macrophages and then ferry it out of the Ertery wall for catabolism and excretion (10). This process,
ommonly referred to as reverse cholesterol transport, seems
o be only one of the anti-atherosclerotic actions of HDL.
ndeed, HDL particles can harbor antioxidant enzymes
uch as paraoxonase-1, an enzyme that can inactivate
otentially proinflammatory phospholipids (11). The HDL
articles can mitigate EC expression of cytokine-induced
eukocyte adhesion molecules. Thus, low levels of circulat-
ng HDL deprive the atheroma’s microenvironment of an
ndogenous antioxidant and anti-inflammatory particle.
Much recent interest in vascular biology has centered on
he endogenous vasodilator molecule nitric oxide (·NO)
12). In addition to its vasorelaxant properties, ·NO can
ombat thrombosis by inhibiting platelet aggregation.
oreover, ·NO seems to have direct anti-inflammatory
ctions on EC, in part mediated by antagonism of the
roinflammatory transcription regulator nuclear factor-
appa B (13,14). Thus, ·NO exerts a variety of atheropro-
ective actions. Interestingly shear stress regulates, endothe-
ial nitric oxide synthase, the enzyme that produces ·NO in
k to the more fibrous lesion involves the migration of smooth muscle cells
, where they secrete extracellular matrix molecules such as fibrillar collagen
hagocytes will imbibe modified lipoproteins such as oxidized low-density
mononuclear phagocytes in the lesions release chemoattractant cytokines,
leukotrienes and prostaglandins, as well as reactive oxygen species (ROS).
beta, they boost their production of extracellular matrix macromolecules,
m and elastin. OxLDL  oxidized low-density lipoprotein.strea
ntima
lear p
ivated
suchC (15,16). Laminar shear stress encountered by EC under
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Inflammation and Atherothrombosis November 7, 2006:A33–46ormal circumstances augments endothelial nitric oxide
ynthase expression and local ·NO production by EC. In
ontrast, the regional release of ·NO likely decreases in
egions of disturbed flow (16). Indeed, areas with high
robability of initial atherosclerotic lesion formation, nota-
ly branch points and flow dividers, display evidence for
nflammatory stimulation (17,18). Thus, the balance be-
ween local proinflammatory and anti-inflammatory pro-
esses probably participates in the preferential formation of
therosclerotic lesions at certain locations in the arterial tree.
Depiction of leukocyte recruitment to early atheroscle-
otic lesions generally focuses on the mononuclear phago-
yte, the precursor of the most numerous white cell in
esions, the lipid-laden macrophage. Indeed, the mononu-
lear phagocyte constitutes the primary effector of the innate
rm of the inflammatory immune response. However, other
lasses of leukocytes such as T and B lymphocytes and mast
igure 3. Maturation of the atherosclerotic plaque. More mature lesions de
nd elastin. Underneath the fibrous cap, a lipid core forms that contains ma
odies, and extracellular lipid accumulations. Proinflammatory mediators r
SMC) can potentiate cell death by apoptosis in the advancing lesion. As
laque’s fibrous cap. In addition, the activated cells in the lesion, notably th
xtracellular matrix. In particular, interstitial collagenases can attack the tr
own elastin required for migration of cells within the lesion, and arter
neurysm formation. During this phase of atherogenesis neovessels form
dventitial layer. IEL  internal elastic lamina; MFC  macrophage foamells also congregate in the arterial intima during athero- wenesis (19). For a full discussion of roles for these cells, see
ovanen (20) and Hansson and Libby (21).
NFLAMMATION AND THE
ROGRESSION OF ATHEROSCLEROSIS
nce established, the atherosclerotic lesion transitions from
he fatty streak, composed primarily of macrophage-derived
oam cells, to a lesion with a more fibrous character (Figs. 2
nd 3). A major cell type involved in the formation of
brofatty lesions, the arterial SMC, also responds to a myriad
f inflammation-associated mediators. Chemoattractants such
s platelet-derived growth factor, locally produced by activated
eukocytes or elaborated by SMC themselves when appropri-
tely stimulated, can signal SMC to enter the intimal layer
rom the media, where they reside in a quiescent state in
ormal arteries (22). The SMC in the intima, some of
a fibrous cap composed of a dense extracellular matrix containing collagen
crophages, dead or dying macrophages, cellular debris including apoptotic
d from activated white cells and endothelial cells and smooth muscle cells
s die within lesions, fewer remain to renew the extracellular matrix in the
crophages, secrete proteinases that can degrade the macromolecules of the
elical collagen fragments, weakening the fibrous cap. Elastases can break
odeling occurs during compensatory enlargement, and in the extreme,
intima, often arising as extensions of vasa vasorum that originate in the
; ROS  reactive oxygen species.velop
ny ma
elease
SMC
e ma
iple h
ial remhich may derive from bone marrow as well as from the
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November 7, 2006:A33–46 Inflammation and Atherothrombosisunica media, can elaborate extracellular matrix (ECM)
olecules that contribute to lesion fibrosis. The arterial
MC manufactures interstitial collagens, elastin, and gly-
osaminoglycans, principal constituents of the complex
CM characteristic of mature atherosclerotic plaques
23,24). Transforming growth factor-beta, a product of
egulatory T cells and other cells associated with athero-
ata, potently stimulates ECM gene expression by arterial
MC (25). During this phase of atherosclerotic lesion
rogression, the lesions assume the characteristic architec-
ure of the established atheroma, including the formation of
fibrous cap that surmounts the typical plaque (Fig. 3).
Underneath the fibrous cap, a lipid-rich region forms,
ften known as the necrotic or lipid core. This central
tructure in the typical atherosclerotic plaque consists of
cellular debris, lipid, and macrophage foam cells. Some
ells within and surrounding this region of the plaque bear
arkers of programmed cell death, or apoptosis (Fig. 3)
26). Proinflammatory cytokines can prime cells for apopto-
ic death after engagement of receptors such as Fas by death
ignals such as Fas ligand on activated T cells (27). Inflam-
ation participates in plaque progression, as indicated by in
igure 4. The thrombotic complications of atherosclerosis. Thrombi comp
anel of this diagram, involves a through-and-through rupture of the plaq
ext and in the legend to Figure 3. The rent in the fibrous cap permits blo
nd smooth muscle cell (SMC) and on microparticles elaborated by the
nvironment of the plaque, including ECs and SMCs, elaborate large amo
brinolytic enzymes also found in the plaque such as urokinase and tissue-t
ormation involves a superficial erosion of the endothelial cells (right panivo experiments that involve interruption of a central eroinflammatory signaling pathway mediated by ligation of
D40 as well as circumstantial evidence based on observa-
ions of human and experimental plaques in situ (28).
NFLAMMATION AND THE
OMPLICATIONS OF ATHEROSCLEROSIS
therosclerotic plaques typically develop in the arterial
ntima over a period of many years, even decades. There,
hese lesions lurk silently until they either produce a
ow-limiting obstruction and provoke ischemia or until
hey trigger thrombosis. The progression of atherosclerotic
esions to occlusive stenoses preoccupied our pathophysio-
ogic concepts and our diagnostic and therapeutic ap-
roaches for most of the 20th century. However, we now
ecognize that occlusive thrombi more frequently compli-
ate noncritically stenotic plaques than those traditionally
eemed the culprit of acute myocardial infarction (Fig. 4).
ecause of positive remodeling or compensatory enlarge-
ent, considerable growth of atheroma can occur without
ubstantial lumenal stenosis (29). Such outwardly remod-
ng atheroma arise by 2 major mechanisms. The first, depicted in the left
brous cap, which has been weakened by the mechanisms described in the
d its coagulation factors to contact tissue factor expressed by macrophages
ls and endothelial cells (EC). Moreover, the activated cells in the local
f plasminogen activator inhibitor-1, a potent inhibitor of the endogenous
asminogen activator. A second common mechanism of coronary thrombus
erhaps caused by endothelial apoptosis or desquamation.licati
ue’s fi
od an
se cel
unts oled plaques may indeed harbor the most intense inflam-
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Inflammation and Atherothrombosis November 7, 2006:A33–46ation and most likely cause acute thrombotic complica-
ions (30).
A physical disruption of atherosclerotic plaques predis-
oses toward thrombus formation. The plaque’s fibrous cap
ypically stands between the blood and highly thrombogenic
aterial in the plaque’s lipid core. A thinned fibrous cap can
reak open, exposing the blood and its coagulation factors to
hrombogenic stimuli such as tissue factor that concentrates
ithin the lesion’s central core. Endothelial erosion also can
recipitate coronary artery thrombosis (Fig. 4) (31). Con-
ergent experimental results and pathological observation
upport a tight link between inflammation, plaque disrup-
ion, and thrombosis (32). Interferon gamma, a prominent
roduct of the activated T lymphocyte, can limit severely the
bility of the SMC to produce new collagen required to
epair and maintain the ECM of the plaque’s fibrous cap
nd hence resist rupture (25). Multiple inflammatory cyto-
ines can augment, alone or in concert, the expression
ithin the plaque of proteinases specialized in degrading the
CM macromolecules that lend strength to the plaque’s
brous cap (33). Members of the matrix metalloproteinase
amily, including interstitial collagenases, likely participate
n this process. Cysteinyl proteinases such as cathepsin S
lso can catabolize elastin, a prominent constituent of the
rterial ECM in plaques (34). Additionally, serine protein-
ses, including neutrophil elastase and plasminogen activa-
ors, may participate in arterial ECM remodeling and
otentially predispose toward plaque disruption and throm-
osis (35). Mediators related to inflammation regulate all of
hese proteolytic enzyme categories.
The plaque’s predominant procoagulant, tissue factor,
lso undergoes regulation by proinflammatory cytokines,
otably CD40 ligand or CD154. In situ studies have
olocalized CD40 ligand-positive cells in the vicinity of
issue factor–bearing macrophages in human atherosclerotic
esions (36). Thus, inflammation tightly regulates the pro-
oagulant potential of the atherosclerotic plaque.
Atherothrombotic events, however, depend on not only
he “solid state” of procoagulants in the plaque itself but also
n the “fluid phase” of the blood (30). Individuals with a
ystemic proinflammatory burden such as the metabolic
yndrome or the diabetic state have elevated levels of
brinogen, the immediate precursor to fibrin, the major
omponent of thrombi (37). Moreover, the major inhibitor
f endogenous fibrinolytic enzymes, plasminogen activator
nhibitor-1, also increases in systemic inflammatory states
uch as those mentioned above (38,39). Thus, in the setting
f local inflammation in the plaque or systemic inflamma-
ion as reflected by the acute-phase response, inflammatory
athways conspire to promote thrombosis and combat
brinolysis. Consequently, inflammation promotes clot for-
ation and instability and underlies the thrombotic aspects
f atherothrombosis as well as lesion initiation and
rogression. hLINICAL IMPLICATIONS OF
NFLAMMATION BIOLOGY IN ATHEROSCLEROSIS
he inflammatory hypothesis of atherothrombosis has ma-
or implications for clinical practice. First, inflammatory
iomarkers possess substantial clinical utility for improving
ascular risk detection beyond that achieved with hyperlip-
demia and traditional risk factors (40). Second, the recog-
ition of atherosclerosis as an inflammatory disease provides
mpetus to seek novel anti-inflammatory therapies with the
otential to treat and prevent acute thrombosis (41).
ISK PREDICTION
ultiple studies in primary and secondary prevention as
ell as acute coronary ischemia have determined that a
iverse set of proinflammatory biomarkers can furnish prog-
ostic information beyond that available from traditional risk
actors. Current analyses of fibrinogen (37); the cytokines IL-1,
L-6, and IL-18 (42– 44); myeloperoxidase (45);
etalloproteinase-9 (46); sCD40L (47,48); lipoprotein-
ssociated phospholipase A2 (49); the adhesion molecules
oluble intercellular adhesion molecule-1, soluble vascular
ell adhesion molecule-1, and P-selectin (50–52); and the
dipokines leptin and adiponectin (53,54) have determined
n association between each of these biomarkers and the risk
f initial or recurrent vascular events; similar observations
ertain to incident hypertension, even among currently
ormotensive individuals (55). However, clinical application
f these findings largely focuses on high-sensitivity
-reactive protein (hsCRP), a pentraxin biomarker of
nnate immunity with analytical chemistry characteristics
avorable to standard outpatient clinical settings. As out-
ined below, such effects prove relevant in primary and
econdary prevention and acute coronary ischemia; they also
nhance our understanding of the mechanisms and underlying
gents commonly used to treat vascular disease (Fig. 5).
HE USE OF hsCRP IN
RIMARY AND SECONDARY PREVENTION
ore than 24 prospective epidemiologic studies of initially
ealthy individuals have evaluated the role of hsCRP as a
eterminant of vascular risk, and all reported positive
ndings. Of these studies, 10 were adequately powered to
valuate the risk prediction role of hsCRP beyond that
ssociated with traditional factors included in global assess-
ent algorithms such as the Framingham Risk Score
49,56–64). When evaluated as a group and despite highly
iverse patient populations, each study showed the impor-
ance of inflammation beyond traditional approaches to risk
rediction (Fig. 6); as shown, these studies consistently find
hat the risk for subjects in the top tertile of hsCRP is
pproximately twice that of those in the lowest tertile. On
his basis, the U.S. Centers for Disease Control and
revention and the American Heart Association endorsed
sCRP as an adjunct to risk prediction in primary preven-
t
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November 7, 2006:A33–46 Inflammation and Atherothrombosision, particularly among individuals at “intermediate” risk
65). Broadly, blood levels of hsCRP 1, 1 to 3, and 3
g/l correspond to low, moderate, and high vascular risk
cross all levels of LDL cholesterol (LDL-C), the Framing-
am Risk Score, and the metabolic syndrome. More recent
nalyses show that these clinical cut points for hsCRP add
elevant prognostic information across all levels of the total/
DL cholesterol and apolipoprotein B/apolipoprotein A ra-
ios, not only after adjustment for traditional covariates but also
fter controlling for diabetes and obesity (66) (Fig. 7). Con-
rary to prior assumptions, the rare individuals who chron-
cally show markedly elevated levels of hsCRP (10 mg/l)
o not seem to represent false-positive cases. Rather, such
ndividuals likely have markedly increased vascular risk,
uggesting that inflammation from several sources can be
athogenic in the vascular endothelium (67). Despite the
requent citation of a few studies as not showing indepen-
igure 5. An inflammatory pathway links risk factors to altered cellular b
roinflammatory risk factors depicted on the top of this diagram activate
acrophage, endothelial cells (EC), smooth muscle cells (SMC), and in
ecrete inflammatory mediators and reactive oxygen species (ROS). The E
soluble form in the peripheral blood. The primary proinflammatory cy
timulate large amounts of IL-6 production by intrinsic vascular wall cells
olecule of a primary proinflammatory cytokine can beget the expression o
hrough the peripheral blood to the liver, where it alters the program of gene
-reactive protein (CRP), serum amyloid A (SAA), fibrinogen, and plasmin
o be a robust prospective indicator of cardiovascular events in a wide s
ediators, including CD40 ligand, which is also shed in a soluble form. T
eedback reinforcement of thrombosis in an inflammatory milieu. AGE 
etalloproteinases; OxLDL  oxidized low-density lipoprotein; PAI-1
ormal T Cell Expressed and Secreted (also known as chemokine ligandent predictive value, the data they report actually agree aith the overall effect estimates seen in larger studies. For
xample, the Rotterdam Study reported an age-adjusted
elative risk for those in the highest compared with the
owest quartile of hsCRP of 2.0 (95% confidence interval
.1 to 3.4), fully consistent with other data (68). Similarly,
ata from the Framingham Heart Study regarding CRP
how strong positivity for stroke (69).
Clinical interest in hsCRP also links in part to the
bservation that its baseline levels associate with in-
reased risk of developing type 2 diabetes mellitus, even
fter adjustment for obesity and other population-based
eterminants of diabetogenesis (70). Multiple studies
how that hsCRP levels predict vascular events beyond
he components of the metabolic syndrome (as defined by
dult Treatment Panel III criteria) or the presence of
rank diabetes (71–73). Although partly caused by asso-
iations between CRP and insulin resistance, such effects
ior and elevated inflammatory markers in peripheral blood. The primary
various cell types prominent in the atherosclerotic plaque, including the
licated lesions, the activated platelet. These various cell types in turn can
ll express leukocyte adhesion molecules that can be shed and recovered in
es, including interleukin-1 (IL-1) and tumor necrosis factor-alpha, can
heightened IL-6 production represents an amplification loop, because 1
y more molecules of IL-6. The IL-6 can function as a messenger, traveling
ession to elicit the acute-phase response. The acute-phase reactants include
activator inhibitor-1. Among these acute-phase reactants, CRP has proved
m of individuals. Activated platelets release a number of inflammatory
D40 ligand can activate tissue factor gene expression, providing a positive
nced glycation end products; Ang II  angiotensin II; MMPs  matrix
sminogen activator inhibitor-1; RANTES  Regulated on Activation,
L5).ehav
the
comp
Cs wi
tokin
. This
f man
expr
ogen
pectru
he C
advare consistent across patient groups with and without
o
(
r
d
v
o
t
e
d
fi
i
s
t
t
d
F
a
A
C Study
D h Stu
F
(
A
A40 Libby and Ridker JACC Vol. 48, No. 9 Suppl A
Inflammation and Atherothrombosis November 7, 2006:A33–46vert evidence of altered glucose homeostasis (74)
Fig. 8). Although the American Diabetes Association
ecently challenged the existence of the metabolic syn-
rome (75), the concerns largely addressed the contro-
ersy surrounding syndrome definition. If the definition
f patients with metabolic syndrome aims to identify
hose with the highest risk of developing both vascular
vents and type 2 diabetes, and given the practical
igure 6. Framingham-adjusted relative risks of future cardiovascular even
nd 3 mg/l in 10 major prospective cohort studies. Data from referenc
therosclerosis Risk in Communities Study; CHS  Cardiovascular H
omplications–Norfolk Study; HPFS  Health Professionals Follow-Up
isease Study; NHS  National Health Study; PHS  Physicians Healt
igure 7. Additive value of high-sensitivity C-reactive protein (hsCRP)
HDLC) ratio (left) and the apolipoprotein (Apo) B:Apo A ratio (right), after a
dapted with permission from Ridker et al. (66).ifficulty of measurement of insulin resistance and hypo-
brinolysis in clinical settings, we and others suggest that
nclusion of hsCRP in formal definitions of metabolic
yndrome may help achieve this goal (76).
Beyond primary prevention, multiple studies have found
hat hsCRP levels in stable patients after myocardial infarc-
ion can predict recurrent infarction and cardiovascular
eath (77,78), a finding consistent with data from patients
ording to baseline levels of high-sensitivity C-reactive protein 1, 1 to 3,
–61,65. *Data from the Reykjavik study are shown in tertiles. ARIC 
Study; EPIC-Norfolk  Evaluation c7E3 for Prevention of Ischemic
; MONICA  Monitoring Trends and Developments in Cardiovascular
dy; PIMA  Pima Indian Study; WHS  Women’s Health Study.
nd above the total cholesterol (TC):high-density lipoprotein cholesterolts acc
es 56
ealthover a
djustment for age, smoking, hypertension, body mass index, and diabetes.
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November 7, 2006:A33–46 Inflammation and Atherothrombosisndergoing elective percutaneous intervention (79) or sur-
ical revascularization (80). However, inflammatory mech-
nisms of atherothrombosis occur in multiple vascular beds,
nd hsCRP levels predict incident peripheral arterial disease
81) as well as incident and recurrent stroke (69,82). Such
redictive ability may reach beyond large-vessel disease. The
otterdam Scan Study recently reported that higher CRP
evels are associated with the presence and progression of
erebral white matter lesions in the periventricular and
ubcortical regions, data with implications for small-vessel
isease progression (83). Supporting the selectivity for CRP
s a predictor of cardiovascular disease, this marker does not
orrelate with either the development of cancer (84) or with
oncardiovascular disease events (85).
sCRP IN ACUTE CORONARY ISCHEMIA
he role of hsCRP in cardiovascular events emerged ini-
ially from observations on patients with acute ischemia and
nstable angina (86–88). Multiple studies have determined
igure 8. Odds ratios of cardiovascular disease (CVD) in U.S. patients
ith diabetes mellitus, metabolic syndrome, and elevated high-sensitivity
-reactive protein (hsCRP) in NHANES (National Health and Nutrition
valuation Survey). Adapted with permission from Malik et al. (74).
igure 9. Prognostic utility of combining high-sensitivity C-reactive pro
schemia in the TIMI 16 and TIMI 18 clinical trials. Adapted with perm
nstable Coronary Syndromes–Thrombolysis In Myocardial Infarction Trial;
herapy With Invasive or Conservative Strategies.hat hsCRP levels at the time of presentation or at hospital
ischarge provide prognostic information on both short-
erm and long-term risk, even in the absence of troponin
levation (89,90). As such, a component of plaque vulner-
bility may not depend on myocardial cell death, an issue
ikely relevant for the development of targeted anti-
nflammatory agents for acute myocardial ischemia.
When used in conjunction with other biomarkers, includ-
ng brain natriuretic peptide and myeloperoxidase, hsCRP
evels also provide incremental evidence of vulnerability to
cute ischemia. Compared with any 1 biomarker used in
solation, investigators for the TIMI (Thrombolysis In
yocardial Infarction) 16 and TIMI 18 trials showed that
ombinations of these emerging biomarkers may provide a
uperior method for the detection of vascular risk, at least in
he setting of acute ischemia (91) (Fig. 9).
sCRP AND THERAPEUTIC INTERVENTIONS
lthough hsCRP is clearly an effective clinical tool for risk
tratification in multiple clinical settings, currently no data
irectly link hsCRP reduction to lower rates of vascular
vents. Nonetheless, diet and exercise—therapies proven to
ower the risk of both heart disease and diabetes—are
ssociated with decreased hsCRP in obese and modestly
verweight patients (92,93). Interestingly, insulin resistance
s associated not only with elevated baseline levels of hsCRP
ut also with greater hsCRP reduction during weight loss.
lthough patients have sustained hsCRP reductions after
astric bypass surgery, intensive lifestyle modifications that
ombine both caloric restriction and moderate-intensity
hysical exercise produce reductions of approximately 30%
94). Agents commonly used to treat diabetes, including
nsulin, metformin, and the peroxisome proliferator acti-
ated receptor-gamma agonists rosiglitazone and pioglita-
one, also lower CRP (95). Whether these effects result
troponin, and brain natriuretic peptide in the setting of acute coronary
from Sabatine et al. (91). OPUS-TIMI  Orbofiban in Patients Withtein,
issionTACTICS  Treat Angina With Aggrastat and Determine Costs of
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epend on improved glycemic control remains controversial.
The use of hsCRP to improve patient selection for
ardiovascular therapies is best shown with regard to
-hydroxyl-3-methylglutaryl reduction with statins. Origi-
ally developed solely as a means to lower LDL-C, statin
gents may possess additional anti-inflammatory properties.
s recently reviewed, statins may be directly immunomodu-
atory, may inhibit expression of cell adhesion molecules,
an induce thrombomodulin and tissue plasminogen activa-
or and thus favorably alter hemostatic balance, and may
ave direct beneficial effects on platelets and smooth muscle
roliferation (96,97).
Initial observations from the CARE (Cholesterol and
ecurrent Events) trial showed clinically that statins lower
RP levels (98); additionally, the benefit of statin therapy
eemed greater among individuals with higher levels of the
nflammatory biomarkers hsCRP or serum amyloid A pro-
ein (77). We now recognize that statins as a class lower
sCRP levels. However, the mechanisms of this effect
emain uncertain, because IL-6 levels do not decline con-
istently with statin therapy. Indeed, statins can reduce the
roduction of CRP by isolated hepatocytes (99,100). Fur-
her, the magnitude of hsCRP reduction expected from the
nitiation of statin therapy cannot be gleaned from the
agnitude of LDL reduction in individual patients (101).
Provocative data now suggest the utility of hsCRP in
onitoring the effectiveness of statins in primary preven-
ion, after stent placement, and in high-risk acute coro-
ary syndromes. Data regarding apparently healthy pa-
ients in the AFCAPS-TexCAPS (Air Force Coronary
therosclerosis Prevention Study–Texas Coronary Ath-
rosclerosis Prevention Study) primary prevention trial
howed that lovastatin decreases hsCRP levels, and
uggested that individuals with low levels of LDL-C and
oncomitant elevations of hsCRP might benefit substan-
ially from statin treatment (102). By contrast, the
FCAPS-TexCAPS trial found no evidence of statin
fficacy among individuals with low levels of both
DL-C and hsCRP. These analyses led to the initiation
f the ongoing large-scale JUPITER (Justification for the
se of Statins in Primary Prevention: an Intervention
rial Evaluating Rosuvastatin) of primary prevention
ith rosuvastatin among individuals with native LDL-C
evels 130 mg/dl, who thus do not qualify for statin
herapy but are at increased risk because of CRP levels 2
g/l (103). The hard end points of the JUPITER trial will
ake its results important not only regarding the inflam-
atory hypothesis of atherosclerosis but also for the con-
eptual basis of extending beyond LDL-C as the sole
ethod for determining those likely to benefit from statin
herapy. With regard to coronary stent placement in pa-
ients with stable angina, statins reduce the increased risk of
ecurrent events associated with elevated CRP levels, inde-
endent again of underlying levels of LDL-C (104,105).
A
IRecent data from the PROVE IT (Pravastatin or Ator-
astatin Evaluation and Infections Therapy)–TIMI 22 and
he REVERSAL (Reversal of Atherosclerosis with Lipitor)
rials further suggest that hsCRP levels achieved by statin
herapy may rival LDL-C levels achieved with these agents.
pecifically, in the PROVE IT–TIMI 22 trial of patients
ith acute coronary syndrome treated with either atorvasta-
in (80 mg) or pravastatin (40 mg), the survival rate of
ndividuals who achieved LDL-C levels below the study
edian (70 mg/dl) improved significantly, data consistent
ith clinical recommendations to aggressively lower lipid
evels in high-risk patients (106) (Fig. 10, left). However,
hat same trial determined that the survival rate of individ-
als with hsCRP levels below the median (2 mg/l) improved
ignificantly as well, regardless of the LDL-C level achieved
Fig. 10, right). Perhaps more importantly, the magnitude
f benefit associated with low levels of hsCRP equaled that
f low LDL, even though the effect was almost entirely
ndependent of lipid lowering. Thus, the greatest clinical
enefit of statin therapy within the PROVE IT–TIMI 22
rial occurred among patients who lowered both LDL-C
70 mg/dl) and hsCRP (2 mg/l) (Fig. 11). Post-hoc
nalyses of these data showed even greater risk reductions at
sCRP levels 1 mg/l.
The REVERSAL trial treated coronary disease patients
ith the same statin agents and doses as PROVE IT.
therosclerotic progression, as measured by intravascular
ltrasound, slowed primarily among individuals who low-
red both LDL-C and hsCRP (107). Similar to the
ROVE IT trial, individuals who achieved aggressive re-
uctions in both LDL-C and hsCRP experienced the
ighest degree of disease regression. Taken together, these
linical data strongly suggest that dual goals of therapy for
igh-risk patients treated with statins should include
DL-C 70 mg/dl as well as hsCRP 2 mg/l. On this
igure 10. Cumulative rate of recurrent myocardial infarction or death
rom cardiac causes among statin-treated patients according to levels of
ow-density lipoprotein cholesterol (LDL-C) (left) and levels of C-reactive
rotein (CRP) (right) both achieved after 30 days in the TIMI 22 trial.
dapted with permission from Ridker et al. (106). TIMI  Thrombolysis
n Myocardial Infarction.
b
i
m
m
I
C
F
t
t
h
i
o
u
t
t
i
w
m
l
t
t
v
m
o
l
r
m
h
r
i
m
q
t
c
g
p
m
o
i
c
s
a
d
e
u
i
h
r
h
d
C
e
u
a
d
i
t
a
b
u
a
c
i
e
m
a
f
v
g
q
f
m
s
fl
n
c
m
r
a
a
R
a
F
f
l
s
p
I
A43JACC Vol. 48, No. 9 Suppl A Libby and Ridker
November 7, 2006:A33–46 Inflammation and Atherothrombosisasis, clinicians may need to measure and monitor hsCRP
n a manner analogous to the methods currently used to
easure and monitor LDL-C, at least if the goal is to
aximize patient benefit with statin therapy.
S CRP MORE THAN A
LINICAL MARKER OF DISEASE?
or a biomarker to be clinically useful, it need only improve
he clinician’s ability to detect disease risk and assist in
herapeutic decision making. As previously outlined,
sCRP has overwhelmingly proven to have these character-
stics. Whether or not a biomarker is in the causal pathway
f disease and can formally fulfill the Koch postulates is
ltimately not relevant for decisions regarding these impor-
ant clinical applications. Nonetheless, it has been of interest
o examine the possibility that CRP might play a direct role
n the atherothrombotic process.
Commonly, CRP localizes in atherosclerotic plaques,
here it can bind to modified LDL, contribute to comple-
ent activation, increase monocyte recruitment, and lead to
esion progression (108,109); CRP also reduces ·NO syn-
hesis, increases the release of endothelin-1, and augments
he function of adhesion molecules and chemokines within
ascular SMC and EC (110,111). In transgenic mice, CRP
ay heighten thrombosis after arterial injury (112). Yet,
verexpression of CRP in atherosclerosis-prone mice has
ittle effect on lesion progression. Additionally, controversy
emains regarding any direct pathogenic effects mediated by
onomeric rather than pentameric CRP (113).
Based on currently available data, we believe that CRP
as potential as a relevant target for therapy, but also
ecognize that evidence to date is both controversial and
ncomplete. Indeed, research on the possible pathogenic
igure 11. Cumulative rate of recurrent myocardial infarction or death
rom cardiac causes among statin-treated patients according to achieved
evels of both low-density lipoprotein (LDL) cholesterol and high-
ensitivity C-reactive protein (CRP) in the TIMI 22 trial. Adapted with
ermission from Ridker et al. (106). TIMI  Thrombolysis In Myocardial
nfarction.echanisms of CRP must proceed carefully to answer Muestions regarding the potential role of CRP as a target for
herapy. Recently released studies indicate at least 7
ommon single-nucleotide polymorphisms in the CRP
ene, including one tri-alleleic single-nucleotide polymor-
hism; haplotypes based on these single-nucleotide poly-
orphisms, however, are responsible for only a tiny fraction
f the population variance in CRP, confirming the major
mportance of environmental factors on inflammatory pro-
esses (114,115). Recently completed human CRP infusion
tudies suggest induction of a substantial proinflammatory
nd prothrombotic state, albeit with limitations (116). The
evelopment of agents that specifically lower CRP without
ffecting platelet function or lipid levels will assist in
nderstanding these issues.
As previously described, the clinical application of hsCRP
s a mature practice, and abundant evidence shows that
sCRP can assist physicians as they evaluate cardiovascular
isk and monitor therapeutic interventions. Whether or not
sCRP ultimately proves to be a direct mediator of vascular
isease will not alter its role as a useful clinical tool.
onclusions. The concept that inflammation governs ath-
rosclerosis and its complications has provided a new
nifying hypothesis regarding the links between risk factors
nd the cellular and molecular alterations that underlie this
isease. This construct not only furnishes new mechanistic
nsight into the disease process but also has begun to
ranslate into changes in clinical practice. The preponder-
nce of present data support the predictive power of
iomarkers of inflammation in broad categories of individ-
als, both those who are apparently well and those with
lready-manifest atherosclerotic cardiovascular disease. The
linical utility of inflammatory biomarkers has engendered
ntense interest and ongoing investigation to evaluate cost-
ffectiveness as a predictive tool beyond conventional risk
arkers. The proposition that hsCRP levels should become
guide for and/or a goal of therapy has received support
rom large-scale clinical trials.
The rapid translation of inflammation biology in cardio-
ascular disease from the laboratory to the clinic serves as a
ratifying example of bench-to-bedside research. Yet, many
uestions remain unsettled in this regard, and we can look
orward to considerable excitement in the future as experi-
ental and clinical studies emerge to help settle the unre-
olved and/or controversial issues. The application of in-
ammation biology to atherosclerosis has already afforded
ew insight into how current interventions, both pharma-
ologic and lifestyle, may reduce cardiovascular risk. Ulti-
ately, the insight that inflammation plays a fundamental
ole in atherosclerosis may lead to novel therapies that target
spects of the inflammatory process smoldering within the
theroma.
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